Company intelligence / Profile preview
Cognigenics
Eagle, Idaho, United Statescognigenics.io ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Cognigenics is in late pre-clinical stage development, working toward phase one trials in late 2024. Their lead product candidate, COGN-201, is entering IND-enabling studies. The company is pursuing breakthrough designation and accelerated review with a goal of market introduction by early 2026, pending FDA approval for clinical trials[1][6].
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- RNA-based therapeuticsDNA-based therapeuticsCRISPR-CasAAV-based delivery
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Contract Research Organizations (CROs) for laboratory research[1]
Beyond the preview
Go deeper on Cognigenics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cognigenics.